The COVID-19 pandemic is and has been an unprecedented event, but there’s also something else to think about.
During this moment in history, we have never had a unified global effort quite like this to find an effective vaccine, and the convergence of technology and medicine that we have access to is allowing researchers to work on a vaccine at break-neck speed.
As of this writing, there are currently 28 COVID-19 vaccines in human trials, and the Trump Administration believes it will have an effective vaccine by 2021.
To get there, the federal government is spending an unprecedented $10 billion.
Now, I don’t have to tell you how explosive the biotech sector has been. Even just a whiff of a potential vaccine is sending stock prices through the roof. For example, the stock price for Altimmune Inc. (Alt), a clinical stage biopharma company, was trading for $1.78 on December 31, 2019. The company received approval to move its vaccine candidate into clinical trials, and the stock price is now above $20.
So think about what will happen when an effective vaccine is actually found.
Today, I wanted to provide you with free access to learn more about the company developing what I call the “Super Vaccine.”
Not only could the viable “Super Vaccine” bring COVID-19 to its knees, it could completely disrupt the $3.2 trillion health-care sector.
But to take part in this story and to learn how to grab your stake of the biotech revolution, you can’t wait.
Cheers and good investing,
Michael A. Robinson